Singhal A, Thomas P, Cook R, Wierenga K, Serjeant G
Medical Research Council Laboratories (Jamaica), University of the West Indies, Kingston.
Arch Dis Child. 1994 Nov;71(5):404-8. doi: 10.1136/adc.71.5.404.
Analysis of the growth abnormalities in sickle cell disease has been limited by the lack of longitudinal observations in individuals, and by an inability to quantitate the observed patterns. To investigate the timing and pattern of the adolescent growth spurt, longitudinal observations of height from the Jamaican cohort study were fitted to a mathematical model of growth (Preece-Baines model 1). The study included 44 children with homozygous sickle cell (SS) disease, 44 age and sex matched subjects with sickle cell haemoglobin C (SC) disease, and 44 age and sex matched controls with normal (AA) haemoglobin. Compared with AA controls, the onset of the adolescent growth spurt was delayed in SS disease by 1.4 years (95% confidence interval 0.8 to 2.0) with no significant sex difference. The age at peak height velocity was delayed by 1.6 years (0.9 to 2.3) in SS compared with AA subjects but the adolescent growth of SS children was otherwise normal and there was no difference in the attained height by age 17.9 years. The growth spurt was not delayed in SC disease. The age at menarche in girls with SS disease (mean (SD) 15.4 (1.3) years) was significantly later than girls with SC disease (13.7 (1.7) years) and those with AA haemoglobin (13.1 (1.3) years) but these genotype differences were no longer significant after controlling for the delay in the adolescent growth spurt. The normally coordinated but slightly delayed pattern of growth and normal adult heights suggests a good prognosis for adolescent growth delay in SS disease. Most children with SS disease can therefore be reassured on the outcome of retarded adolescent growth.
镰状细胞病生长异常的分析受到个体纵向观察数据的缺乏以及无法对观察到的模式进行量化的限制。为了研究青春期生长突增的时间和模式,对牙买加队列研究中身高的纵向观察数据拟合了一个生长数学模型(普里斯 - 贝恩斯模型1)。该研究纳入了44名纯合镰状细胞(SS)病患儿、44名年龄和性别匹配的镰状细胞血红蛋白C(SC)病受试者以及44名年龄和性别匹配的血红蛋白正常(AA)的对照者。与AA对照相比,SS病患儿青春期生长突增的起始延迟了1.4年(95%置信区间0.8至2.0),且无显著性别差异。与AA受试者相比,SS病患儿身高增长速度峰值出现的年龄延迟了1.6年(0.9至2.3),但SS病患儿的青春期生长在其他方面是正常的,到17.9岁时的最终身高没有差异。SC病患儿的生长突增没有延迟。SS病女孩的初潮年龄(均值(标准差)15.4(1.3)岁)显著晚于SC病女孩(13.7(1.7)岁)和AA血红蛋白女孩(13.1(1.3)岁),但在控制了青春期生长突增的延迟后,这些基因型差异不再显著。生长模式正常协调但稍有延迟以及成人身高正常表明SS病患儿青春期生长延迟的预后良好。因此,大多数SS病患儿可以对青春期生长迟缓的结果放心。